C
Chengwen Li
Researcher at University of North Carolina at Chapel Hill
Publications - 74
Citations - 5084
Chengwen Li is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Adeno-associated virus & Transduction (genetics). The author has an hindex of 30, co-authored 73 publications receiving 4314 citations.
Papers
More filters
Journal ArticleDOI
Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity
Joseph E. Rabinowitz,Fabienne Rolling,Chengwen Li,Herve Conrath,Weidong Xiao,Xiao Xiao,R. Jude Samulski +6 more
TL;DR: Overall, in this analysis, type 1 was superior for efficient transduction of liver and muscle, followed in order by types 5, 3, 2, and 4, which established a hierarchy for efficient serotype-specific vector transduction depending on the target tissue.
Journal ArticleDOI
Dystrophin Immunity in Duchenne's Muscular Dystrophy
Jerry R. Mendell,Katherine J. Campbell,Katherine J. Campbell,Louise R. Rodino-Klapac,Louise R. Rodino-Klapac,Zarife Sahenk,Zarife Sahenk,Chris Shilling,Sarah Lewis,Dawn E. Bowles,Steven J. Gray,Chengwen Li,Gloria Galloway,Vinod Malik,Brian D. Coley,K. Reed Clark,Juan Li,Xiao Xiao,Jade Samulski,Scott W. McPhee,R. Jude Samulski,Christopher M. Walker,Christopher M. Walker +22 more
TL;DR: The potential for T-cell immunity to self and nonself dystrophin epitopes should be considered in designing and monitoring experimental therapies for Duchenne's muscular dystrophy.
Journal ArticleDOI
Engineering adeno-associated virus vectors for gene therapy.
Chengwen Li,R. Jude Samulski +1 more
TL;DR: Genetically modifying AAV vectors to increase their transduction efficiency, vector tropism and ability to avoid the host immune response may further increase the success of AAV gene therapy.
Journal ArticleDOI
Several Log Increase in Therapeutic Transgene Delivery by Distinct Adeno-Associated Viral Serotype Vectors
Hengjun Chao,Yuanbo Liu,Joseph E. Rabinowitz,Chengwen Li,Richard Jude Samulski,Christopher E. Walsh +5 more
TL;DR: Significant differences in cFIX expression upon introducing various rAAV serotypes into mouse muscle are found, which have direct bearing on the design of AAV gene therapy clinical trials for hemophilia and should also extend to most therapeutic transgenes.
Journal ArticleDOI
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Dawn E. Bowles,Scott W.J. McPhee,Chengwen Li,Steven J. Gray,Jade Samulski,Angelique S. Camp,Juan Li,Bing Wang,Paul E. Monahan,Joseph E. Rabinowitz,Joshua C Grieger,Lakshmanan Govindasamy,Mavis Agbandje-McKenna,Xiao Xiao,R. Jude Samulski +14 more
TL;DR: This trial established that rationally designed AAV2.5 vector was safe and well tolerated, lays the foundation of customizing AAV vectors that best suit the clinical objective and should usher in the next generation of viral delivery systems for human gene transfer.